The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | JUMP: update on ruxolitinib for myelofibrosis
Francesco Passamonti, MD, University of Insubria, Varese, Italy, talks on the findings of an analysis of data from the JUMP trial (NCT01493414), which investigated the safety and efficacy of ruxolitinib in patients with myelofibrosis. In the analysis, the activity of ruxolitinib was evaluated in four patient risk groups based on the Dynamic International Prognostic Scoring System (DIPSS). At 72 weeks, 82%, 80%, 69%, and 63% of myelofibrosis patients, in order of increasing risk category, exhibited a reduction in spleen length of more than 25%. Overall, these results suggest that earlier intervention with ruxolitinib in patients with myelofibrosis may produce better clinical outcomes. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Francesco Passamonti, MD, has participated in advisory boards or speaker’s bureau for Novartis, BMS, Abbvie and Janssen.
